Search results for "Antihypertensive Agents"

showing 10 items of 184 documents

Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directo…

2020

Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present…

0301 basic medicineAngiotensin-Converting Enzyme InhibitorsDiseaseoutcomescardiovascular diseases; COVID-19; hypertension; infection; outcomes; Betacoronavirus; COVID-19; Cardiovascular Diseases; Humans; Hypertension; Italy; SARS-CoV-2; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronavirus Infections; Pandemics; Pneumonia Viral; Renin-Angiotensin SystemRenin-Angiotensin System0302 clinical medicinecardiovascular diseaseViralAngiotensin Receptor AntagonistsbiologyAngiotensin Receptor AntagonistAntihypertensive AgentItalyoutcomeAngiotensin Receptor BlockersCoronavirus InfectionsCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyhypertensionCoronavirus disease 2019 (COVID-19)Pneumonia ViralBetacoronavirusAngiotensin Receptor Antagonists03 medical and health sciencesPharmacotherapyRenin–angiotensin systemInternal MedicinemedicineHumansIntensive care medicinePandemicsAntihypertensive Agentsoutcomes.BetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2business.industryOutbreakCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin-converting enzymePneumoniacardiovascular diseases; COVID-19; hypertension; infection; outcomesinfectioncardiovascular diseases030104 developmental biologybiology.proteincardiovascular diseases; COVID-19; hypertension; infection; outcomes; betacoronavirus; cardiovascular diseases; humans; hypertension; Italy; angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; antihypertensive agents; coronavirus infections; pandemics; pneumonia viral; renin-angiotensin systembusiness030217 neurology & neurosurgery
researchProduct

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

2016

AbstractWe have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin–angiotensin system; blood pressure lowering even persists for a considerable time after d…

0301 basic medicineBlood Pressure030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesBenzoatesAnimals Genetically ModifiedRenin-Angiotensin SystemGene Knockout Techniques0302 clinical medicineAzilsartanPharmacology (medical)TelmisartanOxadiazolesKidneybiologyStrokemedicine.anatomical_structureCardiovascular DiseasesHypertensionDrug Therapy Combinationmedicine.drugmedicine.medical_specialty03 medical and health sciencesMetabolic DiseasesCulture TechniquesInternal medicineRenin–angiotensin systemmedicineAnimalsHumansAntihypertensive AgentsPharmacologyAngiotensin II receptor type 1business.industryAngiotensin-converting enzymeAtherosclerosisLipid Metabolismmedicine.diseaseDisease Models AnimalGlucose030104 developmental biologyBlood pressureEndocrinologyPathophysiology of hypertensionbiology.proteinBenzimidazolesEndothelium VascularTelmisartanbusinessAngiotensin II Type 1 Receptor BlockersPharmacology & Therapeutics
researchProduct

Real-World Hypertension Prevalence, Awareness, Treatment, and Control in Adult Diabetic Individuals: An Italian Nationwide Epidemiological Survey

2021

Introduction: Hypertesion is the leading cause of morbidity and mortality, worldwide, and its prevalence has been increasing in several countries, including Italy. Aims: To assess hypertension prevalence, awareness, treatment, and control in a real-world sample of adults with self-reported diabetes compared with nondiabetic individuals. Methods: Following the 2018 World Hypertension Day, a nationwide, cross-sectional epidemiological survey on cardiovascular risk factors (“Abbasso la Pressione!”) in 3956 Italian pharmacies enrolled 47217 self-presenting volunteers (≥ 18 years). Participants underwent standardized blood pressure (BP) measurements and answered a questionnaire on cardiovascular…

0301 basic medicineMaleArterial hypertension; Aspects of diabetes; Awareness; Control; Population survey; Adult; Aged; Antihypertensive Agents; Blood Pressure; Cross-Sectional Studies; Diabetes Complications; Female; Humans; Hypertension; Italy; Male; Middle Aged; PrevalenceCross-sectional studyBlood PressurePopulation surveyOverweight0302 clinical medicineAspects of diabeteDiabetes ComplicationEpidemiologyPrevalenceArterial hypertension; Aspects of diabetes; Awareness; Control; Population surveyPopulation survey.Middle AgedAwarenessAntihypertensive AgentItalyHypertensionOriginal ArticleFemalemedicine.symptomCardiology and Cardiovascular MedicineHumanAdultArterial hypertensionmedicine.medical_specialtyDiabetes Complications03 medical and health sciencesPharmacotherapyInternal medicineDiabetes mellitusControlInternal MedicinemedicineHumansAntihypertensive AgentsAgedCross-Sectional Studiebusiness.industryAwarenemedicine.diseaseCross-Sectional Studies030104 developmental biologyBlood pressureConcomitantAspects of diabetesbusinessBody mass index030217 neurology & neurosurgery
researchProduct

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis…

2020

Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, compar…

0301 basic medicineMalePhysiologyMiddle Aged Renin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE-I; ARB; COVID-19; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mortality; sartansSeverity of Illness IndexRenin-Angiotensin System0302 clinical medicineangiotensin converting enzyme inhibitorsRisk FactorsACE-I80 and overMedicineHospital MortalitySartanAged 80 and overIncidence (epidemiology)IncidenceHazard ratioAngiotensin Receptor AntagonistMiddle AgedsartansARBHospitalizationAntihypertensive AgentItalyMeta-analysisHypertensionSartansMolecular MedicineFemaleRisk assessmentHumanmedicine.medical_specialtyAngiotensin converting enzyme inhibitors; ACE-I; Angiotensin receptor blockers; ARB; Sartans; COVID-19; MortalityCoronavirus disease 2019 (COVID-19)Risk AssessmentArticleCOVID−1903 medical and health sciencesAngiotensin Receptor AntagonistsMeta-Analysis as TopicInternal medicineSeverity of illnessHumansAngiotensin receptor blockerMortalityAntihypertensive AgentsAgedPharmacologyACE-I; ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; COVID−19; Mortality; Sartans; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Female; Hospitalization; Humans; Hypertension; Incidence; Italy; Male; Meta-Analysis as Topic; Middle Aged; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Hospital Mortalitybusiness.industryRisk FactorCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin receptor blockersmortalityConfidence intervalangiotensin receptor blockersAngiotensin converting enzyme inhibitors030104 developmental biologyACE-I; ARB; COVID-19 angiotensin converting enzyme inhibitors angiotensin receptor blockers mortality sartansObservational studyAngiotensin converting enzyme inhibitorbusiness
researchProduct

Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension

2021

: The COVID-19 infection has rapidly spread around the world and a second wave is sweeping in many countries. Different clinical and epidemiological aspects characterize the disease and their understanding is necessary to better face the management of the pandemic in progress. The Italian society of arterial hypertension with the SARS-RAS study has contributed significantly to the knowledge of the interaction between inhibition of the renin-angiotensin system and COVID-19 infection. Furthermore, the study results help to understand some of the main aspects related to mortality and morbidity deriving from the infection through a multicentre analysis throughout the national territory.

0301 basic medicineSettore MED/09 - Medicina InternaCross-sectional studyDiseaseComorbiditySeverity of Illness IndexComorbiditiesRenin-Angiotensin System0302 clinical medicineRisk FactorsSex-differences.EpidemiologyPandemicFrailtySars-Cov2Treatment OutcomeItalyAnti-hypertensive therapy; comorbidities; frailty; Sars-Cov2; sex-differencesHypertensionComorbiditiePosition PaperRisk assessmentCardiology and Cardiovascular Medicinemedicine.medical_specialtySex-differenceRisk Assessment03 medical and health sciencesPharmacotherapySex FactorsSeverity of illnessmedicineAnti-hypertensive therapy Sars-Cov2 Frailty Comorbidities Sex-differencesInternal MedicineHumansArterial PressureAnti-hypertensive therapy Comorbidities Frailty Sars-Cov2 Sex-differencesIntensive care medicineAnti-hypertensive therapyAntihypertensive AgentsAnti-hypertensive therapy; Comorbidities; Frailty; Sars-Cov2; Sex-differences; Antihypertensive Agents; Arterial Pressure; COVID-19; Comorbidity; Cross-Sectional Studies; Frailty; Humans; Hypertension; Italy; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors; Treatment OutcomeSettore MED/14 - Nefrologiabusiness.industryCOVID-19medicine.diseaseComorbiditySex-differences030104 developmental biologyCross-Sectional Studiesbusiness030217 neurology & neurosurgery
researchProduct

Resveratrol and Vascular Function

2019

Resveratrol increases the production of nitric oxide (NO) in endothelial cells by upregulating the expression of endothelial NO synthase (eNOS), stimulating eNOS enzymatic activity, and preventing eNOS uncoupling. At the same time, resveratrol inhibits the synthesis of endothelin-1 and reduces oxidative stress in both endothelial cells and smooth muscle cells. Pathological stimuli-induced smooth muscle cell proliferation, vascular remodeling, and arterial stiffness can be ameliorated by resveratrol as well. In addition, resveratrol also modulates immune cell function, inhibition of immune cell infiltration into the vascular wall, and improves the function of perivascular adipose tissue. All…

0301 basic medicineendotheliumEndotheliumAdipose tissueBlood PressureReviewresveratrol030204 cardiovascular system & hematologyResveratrolsirtuin 1AntioxidantsMuscle Smooth VascularCatalysisvascular functionNitric oxidelcsh:ChemistryInorganic Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinecardiovascular diseaseEnosmedicineAnimalsHumansPhysical and Theoretical ChemistryReceptorlcsh:QH301-705.5Molecular BiologyAntihypertensive AgentsSpectroscopybiologySirtuin 1Cell growthChemistryOrganic Chemistryfood and beveragesGeneral Medicinebiology.organism_classificationComputer Science ApplicationsCell biology030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999biology.proteinEndothelium Vascularendothelial nitic oxide synthaseInternational Journal of Molecular Sciences
researchProduct

The Unsolved Conundrum of Optimal Blood Pressure Target During Acute Haemorrhagic Stroke: A Comprehensive Analysis

2019

Intracerebral haemorrhage (ICH) is a devastating cerebrovascular disease, which accounts to 15% of all strokes. Among modifiable risk factors for ICH, hypertension is the most frequent. High blood pressure (BP) is detected in more than 75–80% of patients with ICH. Extremely elevated BP has been associated with early hematoma growth, a relatively frequent occur-rence and powerful predictor of poor outcome in patients with spontaneous ICH. On the other hand, excessively low BP might cause cerebral hypoperfusion and ultimately lead to poor outcome. This review will analyse the most important trials that have tried to establish how far should BP be lowered during acute ICH. These trials have de…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaElevated bpClinical Decision-MakingBlood PressureHaemorrhagic stroke03 medical and health sciences0302 clinical medicinePharmacotherapyHematomaRisk FactorsInternal medicineInternal MedicinemedicineHumansIn patientcardiovascular diseasesStrokeAntihypertensive AgentsCerebral HemorrhageSettore MED/14 - NefrologiaCerebral hypoperfusionBlood pressure · Hypertension · Intracerebral haemorrhage · Strokebusiness.industrymedicine.diseaseStrokeTreatment Outcome030104 developmental biologyBlood pressureCardiologySettore MED/26 - NeurologiaCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgery
researchProduct

Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases. A Consensus Document by the Italian Society …

2021

Hypertension is a major contributor to fatal/nonfatal cardiovascular diseases, and timely identification and appropriate management of factors affecting hypertension and its control are mandatory public health issues. By inducing neurohormonal alterations and metabolic impairment, sleep disorders have an impact on a variety of cardiovascular risk factors, including hypertension, and ultimately increase the risk of cardiovascular events. There is evidence that qualitative and quantitative sleep disorders are associated with resistant hypertension and with impaired circadian blood pressure variations. However, sleep disturbances are often unrecognized, or heterogeneity exists in their managem…

0301 basic medicinemedicine.medical_treatmentSleep disorders.Comorbidity0302 clinical medicineCardiovascular DiseaseSleep Initiation and Maintenance DisordersInsomniaContinuous positive airway pressureSleep Apnea ObstructiveContinuous Positive Airway Pressureblood pressureHeart Disease Risk FactorPrognosisSleep in non-human animalsCircadian RhythmAntihypertensive AgentCardiovascular Diseasessleep disordersmedicine.symptomCardiology and Cardiovascular MedicineRisk assessmentHumancardiovascular riskmedicine.medical_specialtyConsensusSleep ApneahypertensionPrognosiConsensuRisk Assessment03 medical and health sciencesTherapeutic approachInternal MedicinemedicineHumansHealthy LifestyleIntensive care medicineConsensus DocumentAntihypertensive AgentsBlood pressure; Cardiovascular risk; Hypertension; Sleep disorders; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Comorbidity; Consensus; Healthy Lifestyle; Heart Disease Risk Factors; Humans; Hypertension; Prognosis; Risk Assessment; Risk Reduction Behavior; Sleep Apnea Obstructive; Sleep Initiation and Maintenance Disorders; Continuous Positive Airway Pressure; SleepSleep disorderbusiness.industryObstructivePublic healthmedicine.diseaseComorbidity030104 developmental biologyBlood pressureHeart Disease Risk Factorsblood pressure; cardiovascular risk; hypertension; sleep disordersbusinessSleepRisk Reduction Behavior030217 neurology & neurosurgery
researchProduct

In reply-Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme I…

2020

2019-20 coronavirus outbreakAngiotensinsCoronavirus disease 2019 (COVID-19)Pneumonia ViralAngiotensin-Converting EnzymeACE2InflammationAngiotensin-Converting Enzyme InhibitorsPharmacologyArticleAngiotensin Receptor AntagonistsBetacoronavirusRenin–angiotensin systemmedicineHumansPandemicsAntihypertensive AgentsInflammationAngiotensin Receptor Antagonistsbiologybusiness.industrySARS-CoV-2COVID-19Angiotensin-converting enzymeGeneral MedicineCoronavirusAngiotensin-converting enzyme 2biology.proteinAngiotensin Receptor BlockersAngiotensin-Converting Enzyme COVID-19 coronavirus ACE2medicine.symptombusinessCoronavirus InfectionsCoronavirus InfectionsMayo Clinic proceedings
researchProduct

Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study.

2003

Background: The objective of this study was to analyse the relationship of polymorphisms of the angiotensinogen (AGT) gene with the changes in microalbuminuria during 3 years of antihypertensive treatment in a group of young adults with essential hypertension. Methods: Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=23), only β-blockers (n=26), only angiotensin-converting enzyme inhibitors (ACEi) (n=57) or a combination of treatments (n=25). The office blood pressure, biochemical profile and…

AdultBlood GlucoseMalemedicine.medical_specialtyTime FactorsGenotypeAdrenergic beta-AntagonistsAngiotensinogenAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionExcretionDiabetes mellitusInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive AgentsProteinuriaPolymorphism Geneticbusiness.industrymedicine.diseaseEndocrinologyBlood pressureTreatment OutcomeACE inhibitorHypertensionMicroalbuminuriaFemaleGene polymorphismmedicine.symptombusinessmedicine.drugFollow-Up StudiesJournal of human hypertension
researchProduct